Rowley Law PLLC is investigating potential claims against Juno Therapeutics, Inc. (NASDAQ: JUNO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Celgene Corporation. Stockholders will receive $87.00 for each share of Juno Therapeutics, Inc. that they hold. The transaction is valued at approximately $9 billion and is expected to close in the first quarter of 2018.
If you are a Juno Therapeutics, Inc. shareholder and are interested in obtaining additional information regarding this investigation, please fill in the contact form on this page. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Request Information
The submission of this form does not create an attorney-client relationship.